Overall, the studies described in the present dissertation are aimed at the improvement of personalised medicine strategies for various types of cancer. The studies in parts 1 and 2 describe potential novel therapeutic avenues to treat IDH1/2-mutated cancers and the conditions in which they may have optimal effects. The studies described in part 3 may improve risk/benefit assessments for the application of cytotoxic therapies in an individual patient, and the follow-up after the administration of such cytotoxic therapies. These nuances may ultimately improve personalized treatment and management of cancer.
|Qualification||Doctor of Philosophy|
|Award date||22 Dec 2017|
|Publication status||Published - 2017|